Olumiant

Chemical Namebaricitinib
Dosage FormTablet (oral; 2 mg, 1 mg)
Drug ClassKinase inhibitors
SystemMusculoskeletal
CompanyEli Lilly and Company
Approval Year2018

Indication

  • Olumiant is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Olumiant (baricitinib) Prescribing Information2019Eli Lilly And Co